Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 3/20 | 0.38 |
| ▸ | PDE4A | P27815 | 2/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.38 |
| ▸ | PPARG | P37231 | 3/20 | 0.36 |
| ▸ | PPARA | Q07869 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 2/20 | 0.35 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | BACE1 | P56817 | 2/20 | 0.35 |
| ▸ | IKBKB | O14920 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29408241 | 1.00 | PDE4B (0.38) | PDE4BPDE4APDE4CPDE4DPPARG | |
| SCHEMBL22658132 | 0.83 | CNR2 (0.41) | PDE4BPDE4APDE4CPDE4DCNR1 | |
| SCHEMBL22658141 | 0.81 | PDE4B (0.41) | PDE4BPDE4APDE4CPDE4DPPARG | |
| SCHEMBL29408296 | 0.81 | PDE4B (0.41) | PDE4BPDE4APDE4CPDE4DPPARG | |
| SCHEMBL22678869 | 0.80 | PDE4B (0.42) | PDE4BPDE4APDE4CPDE4DPPARG | |
| SCHEMBL22678870 | 0.78 | PDE4B (0.41) | PDE4BPDE4APDE4CPDE4DPPARG | |
| SCHEMBL22658117 | 0.77 | C5AR1 (0.41) | PDE4BPDE4APDE4CPDE4DCNR1 | |
| SCHEMBL22678509 | 0.74 | CYP11B1 (0.53) | PDE4A | |
| SCHEMBL22678306 | 0.71 | CNR2 (0.42) | PDE4BPDE4APDE4CPDE4DHTT | |
| SCHEMBL7583969 | 0.69 | CHRNA7 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085048-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | EPIVARIO INC (US) | 2026-03-26 | — | — | US | disclosed |
| EP-3969439-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | Metabomed Ltd (IL) | 2022-03-23 | — | — | EP | disclosed |
| CN-114127049-A | ACSS2 inhibitors and methods of use thereof | 美特波米德有限公司 | 2022-03-01 | — | — | CN | disclosed |
| WO-2020230134-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD (IL) | 2020-11-19 | — | — | WO | disclosed |
| WO-2020230134-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD (IL) | 2020-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085048-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | ACSS2, GLS2, ACSL3 | PDE4B 2283/4885PDE4A 2933/4885PDE4C 2890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.